Actually we are within one year of potentially having a marketable product, not “years.” Two years ago when the SPA was finalized we were “years” away and few were insisting on a buyout then. The time frame has been accelerated by the EMA AND the Phase 3 is now further along. Selling at the bottom of the wild manipulated swings in biotech stocks is a bad strategy. Many big biotech winners have endured a similar cycle as ADXS. The big money forces you to use patience if you want to win in the end. Patience is the only real tool that you have against them. They have all of the other tools. Money, algos, dishonesty, etc.
News 
Market Data 
Discover 
